An Update on Protein-Bound Uremic Retention Solutes

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 90-94

  Vanholder, Raymond ^a   Schepers, Eva ^a   Pletinck, Anneleen ^a   Neirynck, Nathalie ^a   Glorieux, Griet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AST 120; CARBON; CRESOL; INDICAN; MICROSPHERE; OXIDE; P CRESYLSULFATE; P-CRESYLSULFATE; PLASMA PROTEIN;

ADSORPTION; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PROTEIN BINDING; RENAL REPLACEMENT THERAPY; UREMIA;

ADSORPTION; BLOOD PROTEINS; CARBON; CRESOLS; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MICROSPHERES; OXIDES; PROTEIN BINDING; RENAL DIALYSIS; UREMIA;

EID: 84855177910     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.026     Document Type: Article

References (47)

1. Vanholder R., De Smet R., Glorieux G., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-1943.
2. Jourde-Chiche N., Dou L., Cerini C., Dignat-George F., Vanholder R., Brunet P. Protein-bound toxins-update 2009. Semin Dial 2009, 22:334-339.
3. De Smet R., David F., Sandra P., et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998, 278:1-21.
4. Martinez A.W., Recht N.S., Hostetter T.H., Meyer T.W. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005, 16:3430-3436.
5. de Loor H., Bammens B., Evenepoel P., De Preter V., Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005, 51:1535-1538.
6. Vanholder R., Bammens B., de Loor H., et al. Warning: the unfortunate end of p-cresol as a uremic toxin. Nephrol Dial Transplant 2011, 26:1464-1467.
7. Vanholder R., De Smet R., Waterloos M.A., et al. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995, 47:510-517.
8. Schepers E., Meert N., Glorieux G., Goeman J., Van der Eycken J., Vanholder R. P-cresylsulphate, the main invivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007, 22:592-596.
9. Meijers B.K., Van Kerckhoven S., Verbeke K., et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009, 54:891-901.
10. De Smet R., Van Kaer J., Van Vlem B., et al. Toxicity of free p-cresol: a prospective and cross-sectional analysis. Clin Chem 2003, 49:470-478.
11. Meijers B.K., Bammens B., De M.B., Verbeke K., Vanrenterghem Y., Evenepoel P. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008, 73:1174-1180.
12. Liabeuf S., Barreto D.V., Barreto F.C., et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010, 25:1183-1191.
13. Wang C.P., Lu L.F., Yu T.H., et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis 2010, 211:579-583.
14. Massy Z.A., Barreto D.V., Barreto F.C., Vanholder R. Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors. Atherosclerosis 2010, 211:381-383.
15. Eloot S., Schepers E., Barreto D., et al. eGFR is a poor predictor of concentration of a broad range of uremic toxins. Clin J Am Soc Nephrol 2011, 6:1266-1273.
16. Niwa T., Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994, 124:96-104.
17. Nii-Kono T., Iwasaki Y., Uchida M., et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int 2007, 71:738-743.
18. Faure V., Cerini C., Paul P., Berland Y., Dignat-George F., Brunet P. The uremic solute p-cresol decreases leukocyte transendothelial migration invitro. Int Immunol 2006, 18:1453-1459.
19. Ito S., Osaka M., Higuchi Y., Nishijima F., Ishii H., Yoshida M. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. J Biol Chem 2010, 285:38869-38875.
20. Yamamoto H., Tsuruoka S., Ioka T., et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006, 69:1780-1785.
21. Lekawanvijit S., Adrahtas A., Kelly D.J., Kompa A.R., Wang B.H., Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?. Eur Heart J 2010, 31:1771-1779.
22. Adijiang A., Goto S., Uramoto S., Nishijima F., Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrol Dial Transplant 2008, 23:1892-1901.
23. Barreto F.C., Barreto D.V., Liabeuf S., et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:1551-1558.
24. Lee C.T., Kuo C.C., Chen Y.M., et al. Factors associated with blood concentrations of indoxyl sulfate and p-cresol in patients undergoing peritoneal dialysis. Perit Dial Int 2010, 30:456-463.
25. Lesaffer G., De Smet R., Lameire N., Dhondt A., Duym P., Vanholder R. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000, 15:50-57.
26. Eloot S., Van Biesen W., Dhondt A., et al. Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008, 73:765-770.
27. Basile C., Libutti P., Di Turo A.L., et al. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis. Nephrol Dial Transplant 2011, 26:1296-1303.
28. Fagugli R.M., De Smet R., Buoncristiani U., Lameire N., Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002, 40:339-347.
29. Meert N., Beerenhout C., Schepers E., Glorieux G., Kooman J., Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009, 22:352-357.
30. Meert N., Eloot S., Schepers E., et al. Comparison of removal capacity of two consecutive generations of high flux dialysers during different treatment modalities. Nephrol Dial Transplant 2011, 26:2624-2630.
31. Meert N., Eloot S., Waterloos M.A., et al. Effective removal of protein-bound uraemic solutes by different convective strategies: a prospective trial. Nephrol Dial Transplant 2009, 24:562-570.
32. Meert N., Waterloos M.A., Van Landschoot M., et al. Prospective evaluation of the change of predialysis protein-bound uremic solute concentration with postdilution online hemodiafiltration. Artif Organs 2010, 34:580-585.
33. Schepers E., Glorieux G., Vanholder R. The gut: the forgotten organ in uremia?. Blood Purif 2010, 29:130-136.
34. Bammens B., Verbeke K., Vanrenterghem Y., Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003, 64:2196-2203.
35. Ling W.H., Hanninen O. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992, 122:924-930.
36. Birkett A., Muir J., Phillips J., Jones G., O'Dea K. Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 1996, 63:766-772.
37. Meijers B.K., De Preter V., Verbeke K., Vanrenterghem Y., Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010, 25:219-224.
38. Schulman G., Agarwal R., Acharya M., Berl T., Blumenthal S., Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006, 47:565-577.
39. Kikuchi K., Itoh Y., Tateoka R., Ezawa A., Murakami K., Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2997-3002.
40. Ueda H., Shibahara N., Takagi S., Inoue T., Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007, 11:189-195.
41. Akizawa T., Asano Y., Morita S., et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009, 54:459-467.
42. Ueda H., Shibahara N., Takagi S., Inoue T., Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008, 30:856-860.
43. Meijers B.K., Weber V., Bammens B., et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artif Organs 2008, 32:214-219.
44. Meijers B.K., Verhamme P., Nevens F., et al. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant 2007, 7:2195-2199.
45. Evenepoel P., Bammens B., Verbeke K., Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006, 70:794-799.
46. Pham N.M., Recht N.S., Hostetter T.H., Meyer T.W. Removal of the protein-bound solutes indican and p-cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008, 3:85-90.
47. Vanholder R., Meert N., Van Biesen W., et al. Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?. Nat Clin Pract Nephrol 2009, 5:130-131.